June 30, 2021
Article
NRG1 fusions, which are often first detected by RNA-based sequencing, confer a more molecularly, pathologically, and clinically diverse subtype of lung cancer compared with historical hypotheses.
June 24, 2021
Video
Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.
June 05, 2021
Article
Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.
February 23, 2021
Video
John V. Heymach, MD, PhD, discusses the potential utility of afatinib in NRG1 fusion–positive non–small cell lung cancer.
February 17, 2021
Video
Stephen Liu, MD, discusses the rationale for examining afatinib in patients with non–small cell lung cancer harboring NRG1 fusions.
January 28, 2021
Article
January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.